News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Upsher-Smith Laboratories Receives Final NDA Approval For Vogelxo™ (Testosterone) Gel CIII


6/5/2014 8:36:56 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MAPLE GROVE, Minn.
, June 4, 2014 /PRNewswire/ -- Upsher-Smith Laboratories, Inc., today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Vogelxo (testosterone) gel for topical use CIII. The company is preparing to launch Vogelxo in the near future.

Upsher-Smith Laboratories, Inc.

About Upsher-Smith
Upsher-Smith Laboratories, Inc., founded in 1919, is a growing pharmaceutical company dedicated to its mission of Advancing Pharmacotherapy. Improving Life. With capabilities ranging from early-stage research to delivering on-market products, Upsher-Smith is committed to offering quality products that enable people to live life to its greatest potential. Upsher-Smith's approach to product development and partnering has resulted in a broad range of both branded and generic therapeutic solutions to address patients' needs. The Company has a particular focus on developing therapies for people living with central nervous system (CNS) conditions, such as seizure disorders, and has a robust pipeline of promising CNS compounds in various stages of development. For more information, visit www.upsher-smith.com.

Please see Full Prescribing Information, including Boxed Warning, at http://tinyurl.com/mc7baos.

Logo - http://photos.prnewswire.com/prnh/20130520/NY17281LOGO

SOURCE Upsher-Smith Laboratories, Inc.



Help employers find you! Check out all the jobs and post your resume.
Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES